NPO Microgen launches a production area for botulinum toxins

| By | Import Substitution, Microgen, Nacimbio, Rostec

NPO Microgen, a subsidiary of Nacimbio holding company of Rostec Corporation, is launching a new modern production area to manufacture Relatox, the only Russian botulinum toxin type A. The planned capacity of new production facility is up to 200 thousand packages a year.

The production area has successfully passed the qualification and validation procedures and will be put into operation at Ufa branch of NPO Microgen by the end of 2018. The project is being implemented in accordance with the GMP standards that meet the international requirements for manufacturing and quality control of medicinal products.

“The launch of the new production area will improve the results of the company in the implementation of import substitution policy in the pharmaceutical industry in such sectors as cosmetology and neurology. The high-tech equipment will ensure the quality control of manufacturing at the best world-class level,” said Sergey Goryunov, the First Deputy General Director of NPO Microgen.

The new production area will accommodate the entire set of technological equipment, including freeze-drying machine, sterile filling unit, and decontamination gateway which performs the full cycle of disinfection for the vials before labeling and packaging stages.

GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.